Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics-Reference-Cited by-同舟云学术

Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics

Published:2018-02 Issue:1 Volume:38 Page:51-57
ISSN:2096-5230
Container-title:Current Medical Science
language:en
Short-container-title:CURR MED SCI

Author:

Zhou Ji-hao,Lin Hai-qing,Shen Qi,Hu Li-na,Li Guo-qiang,Sun Xiong-fei,Zhang Xin-you

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Biochemistry

Link

http://link.springer.com/article/10.1007/s11596-018-1845-x/fulltext.html

Reference18 articles.

1. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood, 2016, 127(1): 53–61

2. Mayer RJ, Davis RB, Schiffer CA, etal. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med, 1994, 331(14): 896–903

3. Bloomfield CD, Lawrence D, Byrd JC, etal. Frequency of prolonged remission duration after highdose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res, 1998, 58(18): 4173–4179

4. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J, 2016,6(7): e441

5. Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood, 2013,121(1): 26–28

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry;Clinical Lymphoma Myeloma and Leukemia;2022-10

2. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients;Hematology;2021-01-01